FOMX - Foamix Pharmaceuticals Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.5900
+0.0500 (+1.41%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.5400
Open3.5400
Bid3.15 x 800
Ask3.77 x 1200
Day's Range3.4800 - 3.6084
52 Week Range3.2100 - 7.6000
Volume160,419
Avg. Volume348,391
Market Cap194.877M
Beta (3Y Monthly)2.39
PE Ratio (TTM)N/A
EPS (TTM)-1.97
Earnings DateFeb 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.50
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1

    REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 14, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on.

  • GlobeNewswire25 days ago

    Foamix Announces Appointment of Sharon Barbari to Board of Directors

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Sharon Barbari to its Board of Directors. “I am honored to join Foamix’s Board of Directors and I look forward to helping guide the company through its anticipated upcoming pivotal milestones for its lead candidates FMX101 and FMX103,” said Ms. Barbari. Ms. Barbari joins Foamix’s Board with over 40 years of pharmaceutical and biotechnology experience.

  • Are Foamix Pharmaceuticals Ltd.’s (NASDAQ:FOMX) Interest Costs Too High?
    Simply Wall St.26 days ago

    Are Foamix Pharmaceuticals Ltd.’s (NASDAQ:FOMX) Interest Costs Too High?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...

  • GlobeNewswire2 months ago

    Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. “Submission of this NDA is yet another important milestone for Foamix, and potentially brings us one step further to commercial launch of FMX101,” commented David Domzalski, Chief Executive Officer.

  • Is Foamix Pharmaceuticals Ltd (FOMX) A Good Stock To Buy?
    Insider Monkey2 months ago

    Is Foamix Pharmaceuticals Ltd (FOMX) A Good Stock To Buy?

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]

  • Simply Wall St.2 months ago

    Could Foamix Pharmaceuticals Ltd.’s (NASDAQ:FOMX) Investor Composition Influence The Stock Price?

    A look at the shareholders of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to Read More...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FOMX earnings conference call or presentation 9-May-18 12:30pm GMT

    Q1 2018 Foamix Pharmaceuticals Ltd Earnings Call

  • GlobeNewswire3 months ago

    Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Matt Wiley as Chief Commercial Officer. “Matt has an exceptional commercial record in pharmaceuticals and brings valuable experience and depth of knowledge in marketing, market access, and product launches,” said David Domzalski, Chief Executive Officer of Foamix. Matt Wiley joins Foamix with more than 20 years of commercial experience across a broad range of specialty pharmaceutical categories.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...

  • GlobeNewswire3 months ago

    Foamix Announces Appointment of Anthony Bruno to Board of Directors

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Anthony Bruno to its Board of Directors, replacing Darrell Rigel, M.D. who has resigned from the Board and will become a consultant to the company. “We are delighted to welcome Tony to our Board of Directors,” said Dr. Stanley Hirsch, Chairman of the Board of Foamix.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of FOMX earnings conference call or presentation 8-Nov-18 1:30pm GMT

    Q3 2018 Foamix Pharmaceuticals Ltd Earnings Call

  • Foamix (FOMX) Reports Q3 Loss, Lags Revenue Estimates
    Zacks3 months ago

    Foamix (FOMX) Reports Q3 Loss, Lags Revenue Estimates

    Foamix (FOMX) delivered earnings and revenue surprises of -22.58% and -21.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Reuters3 months ago

    Foamix's treatment for common skin condition meets late-stage trial goals

    Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials. The treatment, code-named FMX103 and made up of an antibiotic commonly used to treat infections, significantly reduced inflammatory lesions, compared to a foam without the antibiotic, minocycline. The two late-stage studies enrolled over a thousand patients suffering from papulopustular rosacea, which causes lesions to break out on the face, and the mostly commonly reported side effects were upper respiratory tract infections, the company said.

  • Implied Volatility Surging for Foamix (FOMX) Stock Options
    Zacks4 months ago

    Implied Volatility Surging for Foamix (FOMX) Stock Options

    Investors need to pay close attention to Foamix (FOMX) stock based on the movements in the options market lately.

  • Simply Wall St.4 months ago

    Does Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Have A High Beta?

    If you own shares in Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...